Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations.
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial wil
AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As C
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates
AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.
AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca’s strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Ph
Utvecklingen i sammandrag
Totala intäkter för första halvåret ökade med 1 %; Bruttomarginalen för kärnverksamheten över 83%, ökning med 1 procentenhet
Starka totala intäkter, gynnat av intäkter från externa samarbeten, stöttar tilltagande investeringar i FoU för att utveckla forskningsportföljen; FoU-investeringarna ökade med 24 % under första halvåret
Effektivitetsprogram avseende kärnve
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival.
AstraZeneca today announced that it has entered an agreement with Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for asthma and chronic obstructive pulmonary disease (COPD) in Japan
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis.
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD).
AstraZeneca today announced a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease.
AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT.
AstraZenecas Sommarforskarskola med spetsplatser för 14 - 17 åringar som vill ha extra utmaningar
Study also found no evidence of increased risk of hospitalisation for heart failure for DPP-4 inhibitors compared with sulfonylureas
Data in oral presentation demonstrate that the investigational combination of dapagliflozin, saxagliptin and metformin resulted in statistically significant reductions in HbA1c in patients uncontrolled on saxagliptin and metformin
AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentationat the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.